{
  "abstract": "Background and Importance Numerous organisations emphasise the importance of proper identification of intravenous preparations to minimise administration errors. The minimum information that should be included is: patient identification details (name, medical record number, and location), active ingredient, dose, and route of administration. For intravenous infusions, additional details should include: final volume, infusion rate and infusion time, preparation date and time, stability or expiration if less than 24 hours.Aim and Objectives To evaluate the identification of intravenous infusions in healthcare units according to the recommendations of the Institute for Safe Medication Practices (ISMP).Material and Methods An observational, descriptive, cross-sectional, and multidisciplinary study conducted in a regional hospital in October 2024.All intravenous infusions administered in the medical and surgical adult inpatient units were evaluated. The following variables were collected: patient identification details, infusion type (continuous or intermittent), active ingredient, dose, and start and end time of the infusion.Results A total of 107 intravenous infusions were analysed: 65 continuous and 42 intermittent.Regarding continuous infusions, 14 (21.5%) included all patient identification details, and 31 (47.7%) specified whether or not an active ingredient was present (17 indicated that it was, and 14 indicated it was not). For the infusions where the active ingredient was listed, 10 specified the dose, 1 did not, and 6 were unknown. The start and end time were listed in 52 (80%) infusions.As for intermittent infusions, none included all patient identification details, and 37 (88.1%) indicated the presence of an active ingredient. Among the infusions where the active ingredient was listed, 21 specified the dose. The start time was listed in 3 (7.1%) infusions, and no infusion included the end time.Conclusion and Relevance The identification of intravenous infusions in our centre does not comply with the ISMP recommendations. Improvement actions should be implemented to standardise labelling and identification protocols for these preparations, in order to minimise the risk of administration errors. Additionally, further studies will be necessary to evaluate the effectiveness of the measures adopted.Conflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "Hospital Universitari De Mataró, Hospital Pharmacy, Mataró, Spain"
      ],
      "name": "M Sancho Riba"
    },
    {
      "affiliations": [
        "Hospital Universitari De Mataró, Hospital Pharmacy, Mataró, Spain"
      ],
      "name": "R Merino Mendez"
    },
    {
      "affiliations": [
        "Hospital Universitari De Mataró, Quality, Mataró, Spain"
      ],
      "name": "N Rubí Montserrat"
    },
    {
      "affiliations": [
        "Hospital Universitari De Mataró, Hospital Pharmacy, Mataró, Spain"
      ],
      "name": "J Vilurbina Perez"
    },
    {
      "affiliations": [
        "Hospital Universitari De Mataró, Hospital Pharmacy, Mataró, Spain"
      ],
      "name": "A Txintxurreta Albizua"
    },
    {
      "affiliations": [
        "Hospital Universitari De Mataró, Hospital Pharmacy, Mataró, Spain"
      ],
      "name": "S Tincu"
    },
    {
      "affiliations": [
        "Hospital Universitari De Mataró, Hospital Pharmacy, Mataró, Spain"
      ],
      "name": "F Sala Piñol"
    }
  ],
  "title": "5PSQ-136 Evaluation of ISMP guidelines in the identification of intravenous infusions: a call for standardisation and risk reduction",
  "uid": "f048d508-014c-5958-af9e-69b493692f46"
}